Anything is possible, but rather unlikely in my opinion. There are too many other investigators involved in the collection of the day and review for this to be an outright fraudulent event.

What a buy...bought at $4.50 and will buy every $1 lower down to $2...this will end up just like Elan....from 21 to 2 and back to 27 and I will be out by then.

When is the RD results due to be released?

Good Grief gfp927z...I have the utmost respect for your scietific understanding of the chemical structures of the ampkine chemical entities and for the amount of time you spend in detailing upcoming cor events, etc. However, (and this is not a criticism, just an observation) in the last 2 or 3 years you have been bullish on cor at almost every peak and bearish at almost every low. So, keep posting, as I think I can make a lot of money trading cor using you as a contrarian indicator..so please post all the negatives you can conjure up, and I'll keep rebuilding my position for the time in the next year or so when something starts to go right for cor and you to start warming back up to it.

Again, I'm not trying to mean or unfeeling....it's just an observation.

Best of luck to you in your future investing!

WMG2

Let's not forget that there were buyers for the 2.9 million shares that were sold Friday.....so some think these prices were a bargain, myself included.

I encourage everyone long COR to take physical delivery of their shares, thereby putting pressure on the naked shorts, or at least place good-until-cancelled orders at prices that you would be willing to part with it. This, too, will put pressure on the short sellers in COR. How effective this would be is questionable, but would not hurt, unless of course you are anticipate selling in the not to distant future.

One just does not risk putting the company in BK because of a lack of capital. Access to capital opens and closes. It's better to take when you can get it.

I raised money for a biotech in the 90's and know that if the industry goes out of favor, and it does from time to time, raising money is next to impossible. EVERY CEO and CFO in the biotech space without a product says the same thing, "take the money when you can get it".

Additionally, having negotiated with big pharma, I can absolutely tell you that there are those within big pharma that would use COR's lack of cash as a lever to get the IP on the cheap. Even if COR could wait them out, not having the capital influences the Big Pharma negotiator to drive for a better deal, else he will be perceived as a weak negotiator by the Big Pharma's executives. Strangely enoungh, it is a hinderance to Big Pharma consumating the deal because of the thinking that COR should be willing to accept a skinny deal just to assure survival. It's just the way the negotiation strategy goes.

Yes, I wish the terms were better, but if the compounds progress, we will make money....good money. If you are a trader, well, you got what you deserved because this is not a trading stock, except on the extremes....which this may well be today or next week. It's just more undervalued now than it was.

My bad...JMP not JPM

It would have been nice if it were JP Morgan!!!!!

Smart move on Stoll's part...

Take the money when it is available....that's the mantra in biotech. Having JP Morgan as the underwriter is very smart. When the stock gets over 5, then JPM will cover it with a buy rating and we will get the institutional coverage the COR so badly needs.

Go going Stoll....well done.

All of you whinning about the stock price should be viewing this price as a gift.

Cor stock price action was rather impressive today. There was a 64,200 share block that was offered at $2.35 all day, was pulled and then went to the market in the early afternoon. That's what drove the price down temporarily, but it came right back.

I like that kind of action. Sign of underlying strength. Of course, there can always be more stock for sale from which this block came.

WMG2

Neuroinv,GFP or anyone else...are the COR compounds reversible or irreversible inhibitors of the active sites that they bind to on the AMPA receptor? A reversible, one that does not form a covalent bound would be much more likely to have less toxicity as a high impact candidate.

Thanks,

--Bill

Pre-market offer $2.20..don't know if it will open there, but this should be a very good day for Cortex longs.

WMG2

gfp927z..not a criticism, just an observation.... from your posts over the last 2 years you seem to have a knack for being bullish at tops and bearish at bottoms. Hence, perhaps your poor stock trading results. Don't be offended, but the more bearish you become, the more comfortable I feel.

Please do keep posting, because most on this board do respect your chemistry/scientific expertise. Too bad about your diary notes, though.

Yes, it was two years ago when Vince told me he felt the patents alone were worth $5 per share....today the patent estate has expanded, but the number of shares are 25% greater, but the proof of concept is greater, also. All told, one could argue $5 is still a fair value.

Vince Simmon had speculated that the patent portfolio alone was, in his opinion, worth about $5 per share. That was in a conversation with him two years earlier.

How would estimate the value of Cortex's patent portfolio?

WMG2

uh, yep....my new prediction is that those who use crystal ball to invest end up eating glass!

Seriously, though, I'm not a day trader so not closing on the high today doesn't change my opinion of COR. I've been a shareholder since 1998 and have made a little money occasionally trading in and out of my core position in Cortex. I will look to sell the a quarter of my position at $8 another quarter at $12 with the rest of the position being held until either a buyout occurs or tox issues render the class of compounds an invalid chemical entity.


wmg2

STOLL- Take on debt in lieu of dilution...

Yes, debt is risky for developing stage companies, but not in this case..COR should obtain $20-30 million mid-term loan and pay it off with Big Pharma upfront proceeds and/or equity purchase at much higher prices or wait to do a secondary at higher prices after the Big Pharma deal is concluded. The loan proceeds would give COR the strength from which to negotiate a better deal with the pharma companies.

In no way should COR issue a secondary offer prior to the Big Pharma deal...that would be very unwise.

It took sixteen trading days after the initial ADHD data was released in March for COR to reach its high $5.94.....don't worry, COR will go much higher.

It's also noteworthy that from a TA view, the daily MACD just gave a buy this morning (the weekly MACD was already in buy mode) and the 3-box Point and Fiqure chart gave a buy when $3.75 was printed. The last two times that COR gave buy signals on the Point and Figure chart, the stock rose for 10 and 11 boxes respectively....that's >$7 per share on this most recent buy signal.

Enjoy the ride and the opportunity to buy more, should you choose.

Prediction: COR finishes the today over the highs of this morning.

wmg2

Thanks for the info nerdseeksablond..EOM

Hi nerdseeksblonde,
For us non-techie types, could you post exactly one goes about setting up the ncbi PubMed to automatically email new articles related to the interested topic identified? Assuming that it isn't terribly involved, of course.

Thanks,
wmg2